165 results on '"Wessels, Judith"'
Search Results
2. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction
3. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
4. Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study
5. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
6. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
7. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
8. Genetic markers of treatment response in rheumatoid arthritis
9. Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose
10. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study
11. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure
12. Integration of Pharmacogenetics and Pharmacogenomics in drug development: Implications for regulatory and Medical decision Making in Pediatric diseases
13. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
14. Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy
15. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
16. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus
17. Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle
18. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis
19. Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate
20. Identity of single-nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: Comment on the article by Wessels et al
21. Pharmocogenetics in the future treatment of rheumatology
22. A Clinical Pharmacogenetic Model to Predict the Efficacy of Methotrexate Monotherapy in Recent-Onset Rheumatoid Arthritis
23. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients
24. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: Comment on the article by Wessels et al
25. Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: Comment on the article by Wessels et al
26. Relationship between Genetic Variants in the Adenosine Pathway and Outcome of Methotrexate Treatment in Patients with Recent-Onset Rheumatoid Arthritis
27. Efficacy and Toxicity of Methotrexate in Early Rheumatoid Arthritis Are Associated With Single-Nucleotide Polymorphisms in Genes Coding for Folate Pathway Enzymes
28. Risico-allelen voor het ontstaan van Type 2 Diabetes Mellitus beïnvloeden de respons op sulfonylureumderivaten
29. Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients
30. An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP)
31. An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP)
32. An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP)
33. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
34. Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients
35. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
36. Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial.
37. CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue.
38. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose
39. Reversible Leukoencephalopathy After Oral Methotrexate: Figure 1.
40. Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.
41. Common polymorphisms in the estrogen receptor-1 may determine risk of hot flashes in early breast cancer patients using tamoxifen.
42. NO ASSOCIATION OF PARAOXONASE-1 Q192R AND THROMBOTIC EVENTS DURING DUAL ANTI-PLATELET THERAPY IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION
43. GENETIC VARIATION IN THE SMARCA2 GENE IS ASSOCIATED WITH CARDIOVASCULAR EVENTS
44. Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians
45. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis
46. SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Letter
47. Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment
48. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
49. Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
50. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.